NKGen Biotech, Inc. Common Stock (NKGN) Revenue History
Annual and quarterly revenue from 2021 to present
NKGN Revenue Over Time (2021–2024)
NKGN Revenue Growth History
0 of 2 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -81.9%
- FY2023 revenue growth
- -100.0%
- FY2024 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $0 | — |
| Q4 2024 | $652K | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
| Q1 2024 | $0 | — |
| Q4 2023 | $0 | — |
| Q3 2023 | $0 | -100.0% |
| Q2 2023 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
NKGN Revenue Analysis (2021–2024)
Current Revenue & Growth
As of June 22, 2026, NKGen Biotech, Inc. Common Stock (NKGN) generated trailing twelve-month (TTM) revenue of $652,000. The most recent quarter (Q1 2025) recorded $0 in revenue, down 100.0% sequentially.
Historical Growth Trajectory
NKGN's historical revenue data shows various trends over time. NKGen Biotech, Inc. Common Stock's highest annual revenue of $426,000 was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including FATE (-52.6% YoY), STTK (-78.3% YoY), and AGEN (+24.5% YoY). Compare NKGN vs FATE →
NKGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NKGNCurrent | $652,000 | - | - | - | |
 FATE | $7M | -52.6% | -26.7% | -2222.4% | |
 STTK | $1M | -78.3% | -36.8% | -5150.8% | |
 AGEN | $114M | +24.5% | +5.3% | -18.0% |
NKGN Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-26,966,000 | - |
| 2023 | $0 | -100.0% | $0 | - | $-29,746,000 | - |
| 2022 | $77K | -81.9% | $59K | 76.6% | $-24,346,000 | -31618.2% |
| 2021 | $426K | - | $396K | 93.0% | $-21,861,000 | -5131.7% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NKGN — Frequently Asked Questions
Quick answers to the most common questions about buying NKGN stock.
Is NKGN's revenue growth accelerating or slowing?
NKGN TTM revenue: $652000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is NKGN's revenue history from 2021 to 2026?
NKGen Biotech, Inc. Common Stock (NKGN) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $652000.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is NKGN's long-term revenue growth rate (CAGR)?
NKGen Biotech, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for NKGN.
Why does NKGN's quarterly revenue fluctuate?
NKGN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. NKGen Biotech, Inc. Common Stock's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is NKGN's revenue distributed by segment?
NKGN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does NKGN's revenue compare to industry peers?
NKGen Biotech, Inc. Common Stock (NKGN) with TTM revenue of $652000.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.